Xenon Pharmaceuticals (XENE) Non Operating Income (2021 - 2026)

Xenon Pharmaceuticals (XENE) has 6 years of Non Operating Income data on file, last reported at $7.5 million in Q1 2026.

• Non Operating Income for Q1 2026 came in at $7.5 million, down 8.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.5 million (down 26.58% YoY), and the FY2025 annual result was $28.2 million, down 31.07% from the prior year.
• Non Operating Income improved to $7.5 million in Q1 2026 per XENE's latest filing, from $5.0 million in the prior quarter.
• Over five years, Non Operating Income peaked at $11.5 million in Q1 2024 and troughed at -$2.7 million in Q1 2022.
• A 5-year average of $6.6 million and a median of $7.6 million in 2023 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2022 and 2025: Non Operating Income surged 3023.55% in 2022, then plunged 42.11% in 2025.
• A 5-year view of Non Operating Income shows it stood at $7.1 million in 2022, then increased by 23.63% to $8.7 million in 2023, then declined by 9.18% to $7.9 million in 2024, then plunged by 36.51% to $5.0 million in 2025, then jumped by 47.8% to $7.5 million in 2026.
• Business Quant data shows XENE's Non Operating Income at $7.5 million in Q1 2026, $5.0 million in Q4 2025, and $6.1 million in Q3 2025.